Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027
LONDON, October 3, 2017 /PRNewswire/ --
Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies
The Alzheimer's Disease Therapeutics and Diagnostics Market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] reached $6.71bn in 2016. The Alzheimer's Disease Therapeutics and Diagnostics Market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] is expected to grow at a CAGR of 15.3% in the second half of the forecast period.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 207-page report you will receive 73 tables and 76 figures- all unavailable elsewhere.
The 207-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] . Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Alzheimer's Disease Market forecasts [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] from 2017-2027, further broken down into: - Alzheimer's Drugs Market - Alzheimer's Diagnostics Market
- Quantitative analysis of the Alzheimer's drug market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market: - Namenda - Aricept - Exelon - Solanezumab - Gantenerumab - Verubecestat
- Quantitative analysis of the Alzheimer's diagnostics market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer's diagnosis from 2017to 2027: - Diagnostic biomarker market - Others
- Profiles of leading pharma companies involved in developing Alzheimer's drugs globally. It contains overviews of the companies' segments, recent mergers and acquisitions and analysis of the companies' recent financial performances. It also includes the details of the drugs for Alzheimer's in the pipeline and forecast of the company drugs available in the market: - Pfizer - Eisai - Actavis - Lundbeck - Daiichi Sankyo - Novartis - TauRx - vTv Therapeutics
- Profiles of leading companies developing diagnostics tests for Alzheimer's disease: - Eli Lilly - Amarantus Biosciences Holdings - Piramal Enterprises - GE Healthcare - Navidea - DiaGenic
- This report also breaks down the revenue forecast for the Alzheimer's Disease Market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] by national market: - US - Germany - France - Italy - Spain - UK - Japan - China - Brazil - India - Russia
- This report covers the qualitative analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] . It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.
- This report shows transcripts of research interviews conducted by Visiongain: - David Hung, Chief Executive Officer of Axovant Sciences Inc. - Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare - Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.
Buy our report today Alzheimer's Disease Therapeutics and Diagnostics Market 2017-2027 [https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027 ] : Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies.
To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/2005/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-2017-2027
List of Companies and Organizations Mentioned in the Report
AbbVie
AB Science
AC Immune
Acadia Pharmaceuticals
Accera
Actavis
Adamas Pharmceuticals
Affiris
Allergan
Amarantus BioSciences
Amorphis
Amgen
Archer Pharmaceuticals
Astellas Pharma
Astex
AstraZeneca
Avanir Pharmaceuticals
Avineuro Pharmaceuticals
Axovant Sciences Inc
AZ Therapies Inc
Baxter
Bayer
Bayer Schering Pharma
Biogen
bioMerieux
Boehringer Ingelheim
Bristol Myers Suibb
Ceregene
Chiesi Farmaceutici
Cognoptix
Cytos
Daiichi Sankyo
DiaGenic
Eisai
Elan
Eli Lilly
EnVivo Pharmaceuticals
European Medicines Agency (EMA)
Forest Laboratories
Forum Pharmaceuticals
Foundation Medical Partners
Functional Neuromodulation
Food and Drug Administration (FDA)
GE Healthcare
General Electric
Genervon Biopharmaceuticals
Genesys Capital
GSK
Hisamitsu Pharmaceutical
Humanetics
IBA Molecular
J&J
Janssen Alzheimer Immunotherapy Research & Development
Janssen Pharmaceutical K. K
Kareus Therapeutics
LabCorp
Luminex
Lundbeck
Medtronic
Merck & Co
Merz
Meso Scale Diagnostics
Metabolic Solutions Development Company
MorphoSys
Nanotherapeutics
National Institute of Health (NIH)
National Institute for Health and Care Excellence (NICE)
Navidea
NextGen Sciences
Novartis
Novo Nordisk
Ono Pharmaceutical
OPKO
Ortho Clinical Diagnostics
Otsuka Pharmaceutical
Oxford BioDynamics
Par Pharmaceuticals
Pfizer
Piramal Enterprises
Piramal Imaging
Proteome Sciences
ProteoTech
Proterra
QR Pharma
Quanterix
Raptor Pharmaceutical
Resverlogix
Roche
Roche Diagnostics
Saladax
Sandoz
Sangamo BioSciences
Sanofi
sGC Pharma
Shionogi
Shire
Siemens Medical Solutions USA
Somalogic
Sonexa Therapeutics
Sun Pharma
T3D Therapeutics
Takeda
Targacept
TauRx
Toyama Chemical
Transition Therapeutics
TransTech Pharma
United Biomedical
VIVUS
Wyeth
To see a report overview please email Sara Peerun on sara.peerun@visiongain.com
Photo:
http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg
SOURCE Visiongain Ltd
